Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 0.71 |
| ▸ | CDK9 | P50750 | 13/20 | 0.71 |
| ▸ | AURKA | O14965 | 9/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.71 |
| ▸ | CDK4 | P11802 | 9/20 | 0.71 |
| ▸ | CDK1 | P06493 | 6/20 | 0.71 |
| ▸ | CDK7 | P50613 | 6/20 | 0.70 |
| ▸ | WEE1 | P30291 | 5/20 | 0.70 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.70 |
| ▸ | FLT3 | P36888 | 4/20 | 0.70 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.70 |
| ▸ | JAK2 | O60674 | 3/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.70 |
| ▸ | PAK4 | O96013 | 3/20 | 0.70 |
| ▸ | ABL1 | P00519 | 3/20 | 0.70 |
| ▸ | FYN | P06241 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168788 | 0.94 | GSK3B (0.88) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL4160054 | 0.91 | GSK3B (0.84) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL4154323 | 0.90 | GSK3B (0.82) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL4165464 | 0.90 | GSK3B (0.81) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL20451990 | 0.89 | GSK3B (0.80) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL5596571 | 0.86 | GSK3B (0.75) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL4164523 | 0.85 | CDK2 (0.81) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL5161475 | 0.83 | GSK3B (0.72) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL2075969 | 0.83 | CDK2 (1.00) | GSK3BCDK2CDK9AURKAAURKB | |
| SCHEMBL2086730 | 0.82 | GSK3B (0.70) | GSK3BCDK2CDK9AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | claimed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | claimed |
| EP-1567522-B1 | PYRIMIDINE COMPOUNDS | CYCLACEL LTD (GB) | 2007-09-19 | — | — | EP | claimed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | claimed |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-04-30 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| EP-3331880-B3 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-01-11 | — | — | EP | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| EP-1567522-B1 | PYRIMIDINE COMPOUNDS | CYCLACEL LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| EP-1567522-B1 | PYRIMIDINE COMPOUNDS | CYCLACEL LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| CN-1711258-A | Pyrimidine compounds | CYCLACEL LTD (GB) | 2005-12-21 | — | — | CN | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | GSK3B 710/4885CDK2 3/4885CDK9 8/4885 |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK3 | GSK3B 976/4885CDK2 8/4885CDK9 9/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | GSK3B 644/4885CDK2 1/4885CDK9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.